Avilar Therapeutics, a Waltham, MA-based biopharmaceutical company focused on extracellular protein degradation, increased Seed funding to $75M.
The round, which had initial funding from Avilar’s founding investor RA Capital Management, was led by Sanofi Ventures, Medical Excellence Capital (MEC), and Astellas Venture Management. Concurrent with this financing, Paulina Hill, PhD, Partner at Sanofi Ventures, will join Avilar’s board of directors. Brian Halak, PhD, from MEC will join as board observer and each of Sanofi Ventures and AVM will also have a board observer seat.
The company intends to use the funds to advance multiple degrader pipeline programs for the treatment of autoimmune, neurological, and other diseases driven by pathogenic extracellular proteins, to expand the platform of proprietary technologies, all custom-built and tailored to designing and building extracellular protein degraders.
Led by President and CEO Daniel Grau, Avilar Therapeutics is a biopharmaceutical company focused on the discovery and development of extracellular protein degraders. The company develops ATACs (ASGPR Targeting Chimeras), a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary discovery platform that includes small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC mediated endocytosis and degradation. This platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. The company is leveraging its platform to create a broad and diverse pipeline of extracellular protein degraders.
FinSMEs
16/02/2023